Document text
Principal Investigator: Michael B Fessler
Organization: NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
Fiscal Year: 2021
Award: $79,472
Funding agency: National Institute of Environmental Health Sciences
New accomplishments to date:
1) Avanti Lipids synthesized enantiomeric 25-hydroxycholesterol (25HC), which will be used as a control for 25HC to help distinguish protein-targeted vs. non-protein-targeted (membrane) effects of this oxysterol in our studies.
2) We have completed several in vivo infections of K18-hACE2-tg mice in which we have treated the mice with 25-OH-cholesterol, infected them with SARS-CoV-2 and then monitored body weight, temperature, survival, and collected specimens that will be analyzed (e.g., lung cDNA, BAL fluid, serum). We do not yet have definitive results on the extent to which 25-OH-cholesterol may be therapeutic against SARS-CoV-2. Further in vivo studies and sample analyses are pending, and we expect clarity within the next few months. We plan to publish our results.
3) We have done preliminary studies in collaboration with the NIAID SARS-CoV-2 Virology Core in which they have tested the therapeutic potential of a panel of oxysterols against in vitro infection of Vero E6 cells with authentic SARS CoV-2 virus. They are still optimizing conditions, and we plan to send them fresh oxysterol plus enantiomeric 25HC.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><25-hydroxycholesterol><Address><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antiinflammatories><Antiinflammatory Agents><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Bioassay><Biologic Assays><Biological Assay><Blood Serum><Body Weight><COVID-19><COVID-19 infection><COVID-19 therapeutics><COVID-19 virus><COVID19><COVID19 infection><COVID19 therapeutics><COVID19 virus><CV-19><CV19><Cell Body><Cell fusion><Cells><Cholesterol><CoV-2><CoV2><Collaborations><Communicable Diseases><Complementary DNA><Coronaviridae><Coronavirus><Enzyme Gene><Enzymes><Epithelial Cells><Family suidae><Human><Hydroxylases><In Vitro><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Investigation><K-18><K-18 conjugate><K18><K18 combination><Lead><Lipids><Liquid substance><Lung><Lung Respiratory System><M mulatta><M. mulatta><Macaca mulatta><Membrane><Mice><Mice Mammals><Mixed Function Oxidases><Mixed Function Oxygenases><Modern Man><Monitor><Monooxygenases><Murine><Mus><NIAID><National Institute of Allergy and Infectious Disease><Organoids><PRRSV><Pathogenicity><Pb element><Pigs><Porcine respiratory and reproductive syndrome virus><Proteins><Publishing><Reporter><Research Specimen><Respiratory Epithelium><Respiratory Infections><Respiratory Tract Infections><Rhesus Macaque><Rhesus Monkey><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Specimen><Structure of respiratory epithelium><Suidae><Swine><Swine Infertility and Respiratory Syndrome Virus><Temperature><Testing><Therapeutic><Toxic effect><Toxicities><Viral><Viral Diseases><Virion><Virus><Virus Diseases><Virus Particle><Work><Wuhan coronavirus><ZIKV><Zika Virus><anti-viral agents><anti-viral drugs><anti-virals><antiinflammatory><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><cDNA><cholest-5-ene-3 beta,25-diol><corona virus><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><fluid><global health emergency><hCoV19><heavy metal Pb><heavy metal lead><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><liquid><membrane structure><nCoV2><porcine><pre-clinical safety><preclinical safety><pulmonary><rapid testing><suid><therapeutic evaluation><therapeutic testing><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><tool><viral infection><virology><virus envelope><virus infection><virus-induced disease><zikav>